![](https://ml.globenewswire.com/media/4b5be207-2832-49b4-9e6a-15869e433e16/small/aprea-logo-445pt-png.png)
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
DOYLESTOWN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today provided a corporate update …